Skip to content
Nonprofiteer
← J CRAIG VENTER INSTITUTE INC

Form 990 for tax year 2022

Filed by J CRAIG VENTER INSTITUTE INC.

Totals

Total revenue
$1,132,512
Total expenses
$23,314,207
Contributions and grants received
$16,500,408
Grants paid
$2,934,839
Program service revenue
$0
Investment income
-$15,395,627
Other revenue
$27,731
Total assets, end of year
$56,307,767
Total liabilities, end of year
$9,402,615
Net assets or fund balances, end of year
$46,905,152
Program services expenses (Part IX)
$13,058,660
Management and general expenses
$9,646,212
Fundraising expenses
$609,335
Program service expenses (Part III)
$13,058,660

Program services were 56.0% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1e · Government grants (contributions)

    $14,857,559

  • 1f · All other contributions, gifts and grants

    $1,642,849

  • 3 · Investment income

    total $726,080 · excluded $726,080

  • 7a · Gross sales of assets other than inventory

    securities $9,796,702 · other assets $25,000,000

  • 7b · Less cost or other basis and sales expenses

    securities $9,364,279 · other assets $41,554,130

  • 7c · Gain or loss

    securities $432,423 · other assets -$16,554,130

  • 7d · Net gain or loss

    total -$16,121,707 · excluded -$16,121,707

  • 11a · Other revenue: K-1 PASSTHROUGH

    total $27,731 · unrelated business $27,731

  • 11e · Other revenue, total

    $27,731

Functional expenses

Part IX, the statement of functional expenses.

  • 1 · Grants to domestic organizations and governments

    total $2,890,979 · program services $2,890,979

  • 3 · Grants to foreign organizations and individuals

    total $43,860 · program services $43,860

  • 5 · Compensation of officers, directors and key employees

    total $2,774,325 · program services $384,236 · management and general $2,390,089

  • 7 · Other salaries and wages

    total $9,352,832 · program services $5,709,724 · management and general $3,190,311 · fundraising $452,797

  • 8 · Pension plan contributions

    total $355,411 · program services $178,596 · management and general $163,545 · fundraising $13,270

  • 9 · Other employee benefits

    total $1,130,364 · program services $568,014 · management and general $520,145 · fundraising $42,205

  • 10 · Payroll taxes

    total $763,835 · program services $383,831 · management and general $351,484 · fundraising $28,520

  • 11b · Fees: legal

    total $228,878 · management and general $228,878

  • 11c · Fees: accounting

    total $288,053 · management and general $288,053

  • 11f · Fees: investment management

    total $95,800 · management and general $95,800

  • 11g · Fees: other

    total $300,059 · program services $39,708 · management and general $260,351

  • 12 · Advertising and promotion

    total $19,015 · management and general $19,015

  • 13 · Office expenses

    total $530,272 · program services $175,006 · management and general $352,635 · fundraising $2,631

  • 14 · Information technology

    total $413,380 · program services $11,232 · management and general $402,148

  • 16 · Occupancy

    total $1,158,313 · program services $574,141 · management and general $525,756 · fundraising $58,416

  • 17 · Travel

    total $112,270 · program services $87,252 · management and general $16,156 · fundraising $8,862

  • 19 · Conferences, conventions and meetings

    total $34,969 · program services $34,969

  • 20 · Interest

    total $45,528 · program services $29,972 · management and general $15,000 · fundraising $556

  • 22 · Depreciation, depletion and amortization

    total $558,116 · program services $457,953 · management and general $98,315 · fundraising $1,848

  • 23 · Insurance

    total $420,103 · program services $22,176 · management and general $397,697 · fundraising $230

  • 24a · Other expenses: LAB EQUIPMENT/SUPPLIES

    total $1,797,845 · program services $1,467,011 · management and general $330,834

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $947,992 · end of year $5,102,233

  • 2 · Savings and temporary cash investments

    beginning of year $2,038,044 · end of year $395,507

  • 3 · Pledges and grants receivable

    beginning of year $5,217,629 · end of year $15,575,492

  • 4 · Accounts receivable

    beginning of year $23,013 · end of year $7,507

  • 9 · Prepaid expenses and deferred charges

    beginning of year $588,140 · end of year $311,397

  • 10a · Land, buildings and equipment: cost or other basis

    $14,864,779

  • 10b · Land, buildings and equipment: accumulated depreciation

    $13,006,124

  • 10c · Land, buildings and equipment, net

    beginning of year $43,348,769 · end of year $1,858,655

  • 11 · Investments: publicly traded securities

    beginning of year $37,716,085 · end of year $27,086,686

  • 12 · Investments: other securities

    beginning of year $1,125,276 · end of year $689,927

  • 15 · Other assets

    beginning of year $2,739,406 · end of year $5,280,363

  • 17 · Accounts payable and accrued expenses

    beginning of year $4,784,511 · end of year $2,689,803

  • 19 · Deferred revenue

    beginning of year $2,778,999 · end of year $2,973,249

  • 23 · Secured mortgages and notes payable

    beginning of year $24,971,402 · end of year $0

  • 25 · Other liabilities

    beginning of year $0 · end of year $3,739,563

  • 27 · Net assets without donor restrictions

    beginning of year $60,600,584 · end of year $34,764,101

  • 28 · Net assets with donor restrictions

    beginning of year $608,858 · end of year $12,141,051

Mission and programs · 2022

Mission

J. CRAIG VENTER INSTITUTE (JCVI) IS AN INDEPENDENT 501(C)(3) NONPROFIT ORGANIZATION ADVANCING THE SCIENCE OF GENOMICS COMMITTED TO ACCELERATING FOUNDATIONAL SCIENTIFIC RESEARCH TO DRIVE ADVANCES IN HUMAN HEALTH AND ENVIRONMENTAL SUSTAINABILITY. THIS PAST YEAR JCVI COMMITTED RESEARCH EFFORTS IN HUMAN HEALTH (WITH SPECIAL FOCUS ON THE SARS-COV-2 VIRUS) ENVIRONMENTAL SUSTAINABILITY, SYNTHETIC BIOLOGY, AND SOFTWARE TOOLS AND TECHNOLOGY. 2022 HIGHLIGHTS AND UPDATES ARE AS FOLLOWS:

Activities or mission (Part I)

JCVI IS ADVANCING THE SCIENCE OF GENOMICS THROUGH BOLD INNOVATIONS. OUR MISSION IS TO UNDERSTAND MORE ABOUT THE BIOLOGICAL WORLD, AND TO DEVELOP UNIQUE INSIGHTS AND ANSWERS ABOUT DISEASE, HEALTH, AND THE ENVIRONMENT FOR THE BENEFIT OF ALL.

  • Withheld by Nonprofiteer: this text may name a private individual.

    Expenses $7,241,059 · Grants $2,890,979

  • Withheld by Nonprofiteer: this text may name a private individual.

    Expenses $2,957,902 · Grants $43,860

  • DEPARTMENT OF DEFENSE: WOUND MICROBIOME PROJECT - CHRONIC WOUNDS ARE WOUNDS THAT FAIL TO HEAL AFTER 3 MONTHS UNDER STANDARD OF CARE WOUND MANAGEMENT. DERRICK FOUDS LEADS A STUDY TO GAIN A BETTER UNDERSTANDING OF THE DIFFERENT CLASSES OF MICROBES THAT COULD BE PRESENT IN HUMAN CHRONIC WOUNDS (I.E. THE WOUND MICROBIOME), AND ASK WHETHER SPECIFIC MICROBES OR MICROBIAL COMMUNITIES ARE ASSOCIATED WITH NON-HEALING WOUNDS. LED BY DERRICK FOUTS, PHD, NEXT GENERATION SEQUENCING IS BEING USED TO IDENTIFY AND CATALOG THE MICROBIAL SPECIES OF BACTERIA, FUNGI, AND VIRUSES THAT ARE PRESENT IN CHRONIC WOUND SPECIMENS. COMPUTATIONAL AND BIOINFORMATICS ANALYSES OF THE MICROBIAL COMMUNITY DNA SEQUENCES WILL BE CARRIED OUT TO CHARACTERIZE THE PRESENCE ANY PATHOGENIC, VIRULENCE, AND ANTIMICROBIAL RESISTANCE-RELATED GENES AND PATHWAYS. THE EVENTUAL GOAL IS TO IDENTIFY ANY PATHOGENIC SPECIES OR FEATURES THAT ARE ASSOCIATED WITH NON-HEALING WOUNDS, AND COULD BE USED AS DIAGNOSTIC AND TREATMENT TARGETS OF CHRONIC WOUNDS. THROUGH AN IARPA-FUNDED COLLABORATION WITH INVESTIGATORS AT HARVARD WYSS INSTITUTE, JOHN GLASS, PHD, IS USING IN VITRO CELL CULTURE SYSTEMS TO ASSESS THE CAPACITY OF SARS-COV-2 PROTEINS TO INHIBIT ANTIVIRAL MECHANISMS OF THE HUMAN INNATE IMMUNE SYSTEM THAT WOULD OTHERWISE PREVENT VIRAL REPLICATION IN THOSE CELLS.

    Expenses $1,020,674

  • OTHER: AS PART OF THEIR INAUGURAL GRANT CYCLE, THE CONRAD PREBYS FOUNDATION FUNDED THE INSTITUTES RESEARCH WORK IN BOTH CORONARY ARTERY DISEASE AND SARS-COV-2. HEART DISEASE IS THE LEADING CAUSE OF DEATH IN THE US AND CORONARY ARTERY DISEASE (CAD) IS THE MOST COMMON TYPE OF HEART DISEASE, KILLING ~366,000 PEOPLE ANNUALLY IN THE US. ABOUT 6.7% (18.2 MILLION) US ADULTS HAVE CAD AND ~20% OF DEATHS FROM CAD OCCUR BEFORE AGE 65. A LIST OF GENETIC FACTORS LINKED TO CAD HAS BEEN FOUND OVER THE LAST FEW DECADES. BUT THEY ONLY EXPLAIN A SMALL PORTION OF THE HERITABILITY IN CAD. TO BETTER UNDERSTAND THE GENETICS AND ETIOLOGY OF CAD AT GENOMIC LEVEL, MORE RARE GENETIC VARIANTS NEED TO BE INVESTIGATED. LED BY WEIZHONG LI, THIS PROJECT, ANALYZED THE WHOLE GENOME DEEP SEQUENCE DATA OF A LARGE COHORT OF ~1000 CAD PATIENTS. USING THE CLOUD-BASED GENOME ANALYSIS PIPELINE, HUNDREDS OF TERABYTES OF SEQUENCE DATA WERE PROCESSED AND MILLIONS OF VARIOUS TYPES OF GENETIC VARIANTS WERE IDENTIFIED. A LIST OF VARIANTS ARE FOUND TO BE ASSOCIATED WITH CAD AND THE EXTENT OF DISEASE IN CAD. BY USING MACHINE LEARNING APPROACHES, WE BUILT VERY ACCURATE PREDICTIVE MODELS FOR THE PREDICTION OF CAD RISKS AND DISEASE SEVERITY. EARLY WARNING SYSTEM FOR SARS-COV-2 IMMUNE ESCAPE PROJECT. NEUTRALIZING ANTIBODIES ELICITED AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS (SARS-COV-2) SPIKE PROTEIN IS WIDELY ACCEPTED AS THE MAIN CORRELATE OF PROTECTION. TO BETTER UNDERSTAND THE ROLE OF ANTIBODIES IN NEUTRALIZATION AND PROTECTION, JCVI, LED BY RICHARD SCHEUERMANN, PHD, AND GENE TAN, PHD, IS CONSTRUCTING A PANEL OF CHIMERIC PSEUDOVIRUSES (BASED ON THE VESICULAR STOMATITIS VIRUS PLATFORM) THAT WE HYPOTHESIZE CAN REVEAL THE IMMUNOLOGICAL DOMINANT AND SUBDOMINANT ANTIGENIC REGIONS OF THE SPIKE PROTEIN. NOTABLY, OUR APPROACH CAN IDENTIFY SUBDOMINANT REGIONS WITHIN THE SPIKE THAT ARE HIGHLY CONSERVED EVEN AMONGST SARS-COV-2 VARIANTS OF CONCERN (VOCS). COVID19 CONTINUES TO IMPACT GLOBAL HEALTH, HIGHLIGHTING THE NEED TO DEVELOP NOVEL THERAPEUTICS. MARCELO FREIRE, PHD, AND HIS LABORATORY DISCOVERED THAT SALIVA IS A BIOFLUID IMPORTANT FOR MEASURING THE VIRUS BUT ALSO THE IMMUNE RESPONSE PRESENTING DIVERSE IMMUNE CELL POPULATIONS. WHITIN SALIVA, WE FIND VARIOUS ANTIVIRAL, ANTI-INFLAMMATORY AND ANTI-BACTERIAL FUNCTIONS. DIFFERENT FROM BLOOD, SALIVARY IMMUNE CELLS ARE IN DIRECT CONTACT WITH THE LIVE VIRUS. IN THIS PROPOSAL WE INVESTIGATED (I) THE COMPOSITION OF ANTIVIRAL IMMUNE CELLS, (II) THE PROTEIN SEQUENCE OF ANTIVIRAL MOLECULES DERIVED FROM INNATE IMMUNE CELLS, AND (III) THEIR MECHANISM OF ACTION. THE FREIRE LAB HAVE SUCCESSFULLY COLLECTED SAMPLES FROM COVID-19 AND HEALTHY CONTROL SAMPLES AND INITIATED SEQUENCING OF SALIVA CELLS IN HEALTH AND IN COVID-19. IN ADDITION, WE ALSO RECRUITED SAMPLES LONGITUDINALLY AT JCVI TO EVALUATE HEALTHY VERSUS DISEASE. TO DATE, WE COMPLETED IMMUNOGLOBULIN IMMUNOASSAYS OF ALL OUR SAMPLES INCLUDING INVESTIGATIONS TO CUSTOM ELISA ASSAYS FOR SARS-COV-2 ANTIGENS (RBD, S1, S2, NP PROTEINS). WE HAVE IDENTIFIED THAT SALIVARY IMMUNOGLOBULIN IGA AS HIGHLY SIGNIFICANT COMPARED TO BLOOD PLASMA LEVELS. SEVERAL MARKERS FROM IGG AND IGA RESPONSES WERE FOUND IN SALIVA AS WELL AS PLASMA. SIMPLE LINEAR REGRESSION MODEL VERIFIED SIGNIFICANT CORRELATIONS BETWEEN SALIVA AND PLASMA ANTIBODY RESPONSES, SPECIFICALLY FOR THE IGA (P=0.001), IGG (P=0.037), AND IGM (P=0.0054) SPECIFIC TO THE SARS-COV-2 RECEPTOR BINDING SITE (RBD). THESE ARE ANTIVIRAL MOLECULES THAT HAVE POTENTIAL TO BLOCK VIRAL ACTIVITY. TO TEST THIS FURTHER FROM OUR ASSAYS, JCVI PERFORMED A NEUTRALIZATION ASSAY AND COMPARATIVE ANALYSIS TO UNDERSTAND IF THESE MOLECULES HAVE A FUNCTIONAL RESPONSE. DESPITE THAT SALIVA CONTAINED ROBUST IGA RESPONSE TO THE SARS-COV-2, WHICH WAS EVEN HIGHER THAN PLASMA, MOST OF SALIVA SAMPLES DEMONSTRATED LEVEL OF NEUTRALIZATION OF VESICULAR STOMATITIS VIRUS (VSV) PSEUDOVIRUSES BEARING S OF SARS-COV-2 (RVSV-GFPG*SPIKE). IT WAS CONTRASTED WITH THAT THE PLASMA DISPLAYED A SIGNIFICANT LEVEL OF NEUTRALIZING ACTIVITY EVEN FROM HEALTHY INDIVIDUALS. THESE RESULTS SUGGEST THAT THE ORAL MUCOSAL IMMUNE COMPONENTS COOPERATE WITH SYSTEMIC IMMUNE RESPONSE IN RESPONSE TO THE SARS-COV-2 INFECTION. SALIVA AND PLASMA SAMPLES CONTAINED SIGNIFICANTLY HIGHER LEVELS OF SARS-COV-2 SPECIFIC ANTIBODIES THAN HEALTHY AND WE DISCOVERED MULTIPLE PEPTIDES PRESENT A ROLE AGAINST VIRAL PARTICLES. ULTIMATELY, THIS PROJECT AIMS TO MAP THE SALIVARY MOLECULAR CONTENT WHEN EXPOSED TO THE VIRUS. WE AIM PROVIDE TO THE SCIENTIFIC COMMUNITY A NEW LAYER OF IMMUNE RESPONSE COMPOSITION AND FUNCTION RELATED TO MUCOSAL LINING WHEN FACING VIRAL ATTACK. THIS WILL THEN GUIDE NEW CLINICAL APPROACHES WITH THE FORMATION OF THE THERAPEUTICS THAT EMULATE HOW AND WHY THE MUCOSAL TISSUES KEEP DISEASE IN CHECK. SANJAY VASHEE, PHD, COLLABORATING WITH INVESTIGATORS AT THE UNIVERSITY OF MARYLAND TO USE SYNTHETIC GENOMICS TO DEVELOP A SARS-COV-2 INFECTIOUS CLONE. THEY ARE PAIRING THIS WITH A RAPID, MODULAR REVERSE GENETIC SYSTEM TO ASSESS GENOMIC VARIANTS IDENTIFIED IN THE WEALTH OF GLOBAL SEQUENCING DATA, DEVELOP AND TEST VACCINE CANDIDATES, AND GENERATE NEEDED REAGENTS, INCLUDING FLUORESCENT AND TAGGED VIRUS STRAINS. MARCELO FREIRE, PHD, IS LEADING EFFORTS IN THE DEVELOPMENT OF A SALIVARY SEROLOGICAL AND IMMUNE TESTING. MONITORING SALIVA IMMUNITY PROVIDES NON-INVASIVE MOLECULAR INFORMATION, ESSENTIAL FOR DIAGNOSTICS, AND RESPONSE TO THERAPY DURING THE PANDEMIC. HIS LABORATORY IS COMPARING COVID-19 PATIENTS' BLOOD AND SALIVARY IMMUNOGLOBULINS LEVELS TO FIND BETTER WAYS TO EVALUATE IMMUNE RESPONSE TO SARS-COV-2.

    Expenses $1,839,025

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here. A text marked withheld matched a screen for wording that may name a private individual, such as an honorific or "in memory of". Most of what it withholds names no one; it is withheld so that what does is never shown.

Listed in Part VII

  • VENTER JOHN CRAIG

    CHAIRMAN & CEO

    Total calculated
    $1,208,785
    From this org
    $1,191,065
    From related orgs
    $0
    Other
    $17,720
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $1,175,385
    Bonus
    $0
    Other
    $15,680
    Deferred
    $12,200
    Nontaxable benefits
    $5,520
    Filer's total
    $1,208,785

  • SCHEUERMANN RICHARD H

    DIRECTOR, LA JOLLA CAMPUS

    Total calculated
    $384,236
    From this org
    $355,800
    From related orgs
    $0
    Other
    $28,436
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $347,428
    Bonus
    $0
    Other
    $8,372
    Deferred
    $12,200
    Nontaxable benefits
    $16,236
    Filer's total
    $384,236

  • KOWALSKI HEATHER

    CHIEF OPERATING OFFICER

    Total calculated
    $378,985
    From this org
    $360,452
    From related orgs
    $0
    Other
    $18,533
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $355,385
    Bonus
    $0
    Other
    $5,067
    Deferred
    $12,200
    Nontaxable benefits
    $6,333
    Filer's total
    $378,985

  • MULLEN JILL

    SR. VP OF PHILANTHROPY

    Total calculated
    $338,709
    From this org
    $309,153
    From related orgs
    $0
    Other
    $29,556
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $302,088
    Bonus
    $0
    Other
    $7,065
    Deferred
    $12,200
    Nontaxable benefits
    $17,356
    Filer's total
    $338,709

  • PEAKE ANTONY G

    VP RESEARCH ADMINISTRATION

    Total calculated
    $310,061
    From this org
    $294,619
    From related orgs
    $0
    Other
    $15,442
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $292,068
    Bonus
    $0
    Other
    $2,551
    Deferred
    $11,800
    Nontaxable benefits
    $3,642
    Filer's total
    $310,061

  • YUMUL MARY

    VP OF HUMAN RESOURCES

    Total calculated
    $286,588
    From this org
    $254,449
    From related orgs
    $0
    Other
    $32,139
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $251,951
    Bonus
    $0
    Other
    $2,498
    Deferred
    $10,400
    Nontaxable benefits
    $21,739
    Filer's total
    $286,588

  • STOUT MARTIN

    CHIEF TECHNOLOGY OFFICER

    Total calculated
    $285,806
    From this org
    $257,144
    From related orgs
    $0
    Other
    $28,662
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $248,878
    Bonus
    $0
    Other
    $8,266
    Deferred
    $7,985
    Nontaxable benefits
    $20,677
    Filer's total
    $285,806

  • STAYEAS TIMOTHY

    NETWORK TEAM LEAD

    Total calculated
    $245,200
    From this org
    $216,323
    From related orgs
    $0
    Other
    $28,877
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $214,831
    Bonus
    $0
    Other
    $1,492
    Deferred
    $8,996
    Nontaxable benefits
    $19,881
    Filer's total
    $245,200

  • FOUTS DERRICK

    PROFESSOR

    Total calculated
    $232,198
    From this org
    $201,750
    From related orgs
    $0
    Other
    $30,448
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $199,878
    Bonus
    $0
    Other
    $1,872
    Deferred
    $8,319
    Nontaxable benefits
    $22,129
    Filer's total
    $232,198

  • SINGH INDRESH

    SR. SOFTWARE ENGINEER

    Total calculated
    $228,862
    From this org
    $200,678
    From related orgs
    $0
    Other
    $28,184
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $198,802
    Bonus
    $0
    Other
    $1,876
    Deferred
    $8,355
    Nontaxable benefits
    $19,829
    Filer's total
    $228,862

  • ADELSON JULIE

    VP, LEG. AFFRS/GENERAL COUNSEL

    Total calculated
    $206,454
    From this org
    $197,221
    From related orgs
    $0
    Other
    $9,233
    Hours/week
    20

    Schedule J breakdown matched by us

    Base
    $177,269
    Bonus
    $0
    Other
    $19,952
    Deferred
    $7,200
    Nontaxable benefits
    $2,033
    Filer's total
    $206,454

  • BADR-EL-DIN AMIN PHD

    TRUSTEE

    Total calculated
    $0
    Hours/week
    1

  • MCGRORY JACK

    TRUSTEE (THRU 08/22)

    Total calculated
    $0
    Hours/week
    2

  • NORRBY ERLING

    TRUSTEE

    Total calculated
    $0
    Hours/week
    1

  • RUGGLES RUDY

    TRUSTEE

    Total calculated
    $0
    Hours/week
    1

  • WEI WU

    TRUSTEE

    Total calculated
    $0
    Hours/week
    1

  • WOLF RICHMOND

    TRUSTEE

    Total calculated
    $0
    Hours/week
    1

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 1a · Tax indemnification and gross-up payments
  • 1b · Written policy on the line-1a expenses
  • 2 · Substantiation required before reimbursing expenses
  • 3 · Compensation committee
  • 3 · Independent compensation consultant
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee

Answered no

  • 4a · Severance or change-of-control payment
  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 7 · Other non-fixed payments
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 1A
SCHEDULE J, PART I, LINE 1A: TAX INDEMIFICATION AND GROSS-UP PAYMENTS - CERTAIN AWARDS ARE GROSSED UP FOR INCOME TAX AND INCLUDED AS TAXABLE COMPENSATION.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

The 10 largest by cash amount. The API serves every itemized grant.

Provenance

Return type
form_990
Tax year
2022
Filed
23 October 2023
IRS schema version
2022v5.0
Source object
202303039349301600

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.